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The Arg/N-degron pathway targets proteins for degradation by
recognizing their N-terminal or internal degrons. Our previous
work produced double-knockout (2-KO) HEK293T human cell lines
that lacked the functionally overlapping UBR1 and UBR2 E3 ubiq-
uitin ligases of the Arg/N-degron pathway. Here, we studied these
cells in conjunction with RNA-sequencing, mass spectrometry (MS),
and split-ubiquitin binding assays. 1) Some mRNAs, such as those
encoding lactate transporter MCT2 and β-adrenergic receptor
ADRB2, are strongly (∼20-fold) up-regulated in 2-KO cells, whereas
other mRNAs, including those encoding MAGEA6 (a regulator of
ubiquitin ligases) and LCP1 (an actin-binding protein), are com-
pletely repressed in 2-KO cells, in contrast to wild-type cells. 2)
Glucocorticoid receptor (GR), an immunity-modulating transcrip-
tion factor (TF), is up-regulated in 2-KO cells and also physically
binds to UBR1, strongly suggesting that GR is a physiological sub-
strate of the Arg/N-degron pathway. 3) PREP1, another TF, was
also found to bind to UBR1. 4) MS-based analyses identified ∼160
proteins whose levels were increased or decreased by more than
2-fold in 2-KO cells. For example, the homeodomain TF DACH1 and
the neurofilament subunits NF-L (NFEL) and NF-M (NFEM) were
expressed in wild-type cells but were virtually absent in 2-KO cells.
5) The disappearance of some proteins in 2-KO cells took place
despite up-regulation of their mRNAs, strongly suggesting that
the Arg/N-degron pathway can also modulate translation of spe-
cific mRNAs. In sum, this multifunctional proteolytic system has
emerged as a regulator of mammalian gene expression, in part
through conditional targeting of TFs that include ATF3, GR,
and PREP1.
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Regulated protein degradation protects cells from abnormal(e.g., misfolded or aggregated) proteins and also modulates
the levels of proteins that evolved to be short-lived in vivo. The bulk
of intracellular protein degradation is mediated by the ubiquitin
(Ub)-proteasome system (UPS) and by the autophagosome-
endosome-lysosome system, with molecular chaperones playing
essential roles in both processes (1–6). UPS comprises pathways
that have in common two classes of enzymes, Ub ligases and
deubiquitylases. An E3-E2 ligase recognizes a protein substrate
through its feature called a degradation signal (degron) and
conjugates a small protein Ub, usually in the form of a poly-Ub
chain, to an amino acid residue of a substrate, usually its internal
lysine. Deubiquitylases mediate, in particular, deubiquitylation
of Ub-conjugated proteins (1–7). The 26S proteasome is a
multisubunit ATP-dependent protease that binds to a poly-Ub of
a ubiquitylated protein, unfolds the protein, and cleaves it to
peptides that range from ∼3 to ∼25 residues (8–10).
N-degron pathways (they were previously called “N-end rule
pathways”) are proteolytic systems that can recognize proteins
containing N-terminal (Nt) degrons called N-degrons. The tar-
geted proteins are destroyed by the 26S proteasome and/or
autophagy pathways in eukaryotes, and by the ClpS-ClpAP pro-
tease in bacteria (Fig. 1 and SI Appendix, Fig. S1) (2, 11–32).
Specific determinants of an N-degron include a destabilizing Nt-
residue of a protein, its internal lysine (or lysines) that functions as
a site of polyubiquitylation, and a segment used by the proteasome
to initiate degradation (2, 12).
The currently known eukaryotic N-degron pathways comprise
the Arg/N-degron pathway (it targets, in particular, specific
unacetylated Nt-residues); the Ac/N-degron pathway (it targets,
in particular, the Nα-terminally acetylated [Nt-acetylated] Nt
residues); the Pro/N-degron pathway (it targets, in particular, the
Nt-Pro residue); the Gly/N-degron pathway (it targets the un-
modified Nt-Gly residue); and the fMet/N-degron pathway (it
targets Nt-formylated proteins) (Fig. 1 and SI Appendix, Fig. S1)
(2, 11–28, 30–34).
Initially, most N-degrons are not active (pro-N-degrons). Ac-
tive N-degrons are produced either constitutively (for example,
cotranslationally) or via regulated steps. Many nonprocessive
intracellular proteases, including aminopeptidases, caspases,
calpains, separases, and cathepsins, function as “upstream” com-
ponents of N-degron pathways that generate active N-degrons,
since a cleavage of a protein can produce a C-terminal (Ct)
fragment bearing a destabilizing Nt-residue (2, 23, 30). N-degrons
can also be formed (activated) through enzymatic Nt-acetylation,
Nt-deamidation, Nt-oxidation, Nt-arginylation, Nt-leucylation,
and Nt-formylation of specific proteins or their Ct-fragments
(Fig. 1 and SI Appendix, Fig. S1) (2, 16, 17, 19, 28). Recognition
components of N-degron pathways are called N-recognins. They
are E3 Ub ligases or other proteins (for example, mammalian p62
or bacterial ClpS) that can recognize N-degrons (2, 16, 25, 27, 29).
In cognate sequence contexts, all 20 amino acids of the genetic
code can act as destabilizing Nt-residues (SI Appendix, Fig. S1).
Consequently, many proteins in a cell are conditionally short-lived
substrates of N-degron pathways, either as full-length proteins or
as Ct-fragments. An additional and functionally important feature
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of most E3 N-recognins is that they can target, through their
multiple binding sites, not only N-degrons but other degradation
signals as well. This ability of N-recognin E3s further expands the
range of substrates targeted by N-degron pathways (Fig. 1) (2, 26,
35, 36).
Regulated degradation of proteins and their natural fragments
by N-degron pathways has been shown to mediate a remarkably
broad range of biological processes, including the sensing of
oxygen, nitric oxide (NO), heme, and short peptides; the elimi-
nation of misfolded proteins and of proteins retrotranslocated to
the cytosol from other compartments; the control of subunit
stoichiometries in protein complexes; a suppression of neuro-
degeneration and regulation of apoptosis; the control of DNA
repair, transcription, replication, and chromosome cohesion/
segregation; the regulation of chaperones, cytoskeletal proteins,
G proteins, autophagy, gluconeogenesis, peptide transport,
meiosis, circadian rhythms, cell migration, fat metabolism,
adaptive and innate immunity, the cardiovascular system, neu-
rogenesis and spermatogenesis; and also plant defenses against
pathogens, plant cell differentiation, the sensing of oxygen and
NO, and many other processes in plants (2, 11–38 and
refs. therein).
To keep notations uniform, human (Homo sapiens, hs) genetic
terms (all-uppercase letters) are used below to denote both hu-
man, mouse (Mus musculus, mm) and yeast (Saccharomyces
cerevisiae, sc) genes and proteins. scUBR1 encodes the 225-kDa
RING-type E3, the sole N-recognin of the S. cerevisiae Arg/
N-degron pathway. Unmodified N-terminal Arg, Lys, His, Leu,
Phe, Tyr, Trp, Ile, and Met (if Nt-Met is followed by a bulky
hydrophobic residue) are termed “primary” destabilizing Nt-
residues in that they can be bound by the type-1 and type-2
sites of scUBR1 (2, 15, 16). In contrast, Nt-Asp and Nt-Glu
are destabilizing, owing to their Nt-arginylation by scATE1
arginyltransferase (R-transferase). The Nt-conjugated Arg can
be recognized by scUBR1. Nt-Asn and Nt-Gln are destabilizing
because scNTA1 Nt-amidase can convert them to Nt-
arginylatable, Nt-Asp and Nt-Glu (SI Appendix, Fig. S1G)
(2, 32).
In contrast to S. cerevisiae, the mammalian Arg/N-degron
pathway is mediated by at least four E3 N-recognins: the
200-kDa UBR1 and UBR2; the 570-kDa UBR4 (p600, BIG);
and the 300-kDa UBR5 (EDD1, HYD) (Fig. 1) (2, 16, 25).
Another, non-E3 N-recognin of this pathway is p62, an
autophagy-regulating protein (27). hsUBR1 and hsUBR2 E3s
are sequelogous† [similar in sequence (39)] to each other and to
S. cerevisiae scUBR1. In contrast, sequelogies (39) (sequence
similarities) between hsUBR1/hsUBR2 and hsUBR4 or hsUBR5
are confined largely to their ∼80-residue folded UBR domains,
which bind to N-terminal Arg, Lys, or His (2, 16). In S. cerevisiae,
scNTA1, an Asn/Gln/Nt-amidase, can deamidate either Nt-Asn
or Nt-Gln, whereas animals and plants contain two Nt-amidases,
the Nt-Asn-specific NTAN1 and Nt-Gln-specific NTAQ1 (Fig. 1
and SI Appendix, Fig. S1G) (2, 16).
In multicellular eukaryotes, Nt-arginylation encompasses not
only Nt-Asp and Nt-Glu but also Nt-Cys, after its oxygen/NO-
dependent oxidation to Nt-arginylatable Nt-Cys-sulfinate or
Fig. 1. The mammalian Arg/N-degron pathway (2, 15, 16). Single-letter abbreviations denote Nt-residues. The rest of a protein substrate is denoted by a
yellow oval. The Arg/N-degron pathway targets proteins for degradation either by the 26S proteasome (via UBR1, UBR2, UBR4, and UBR5 E3s) or by the
autophagy-lysosome pathway (via p62 N-recognin). The E3s cited above can recognize not only the indicated (primary destabilizing) Nt-residues of
protein substrates but also specific non-N-terminal degrons in proteins that lack Arg/N-degrons. The terms “primary,” “secondary,” and “tertiary” denote
specific classes of destabilizing Nt-residues. The Nt-amidases NTAN1 and NTAQ1 convert, respectively, Nt-Asn and Nt-Gln to the Nt-residues Asp and Glu.
C* denotes an oxidized N-terminal Cys residue, either Cys-sulfinate or Cys-sulfonate. These derivatives of Nt-Cys can be produced in vivo through reactions
that involve oxygen and NO. The Arg-tRNA-protein transferase (R-transferase) ATE1 conjugates Arg (with Arg-tRNA as a cosubstrate) to the Nt-Asp, Nt-
Glu, or (oxidized) Nt-Cys residues. Hemin (Fe3+-heme) down-regulates both the activity of R-transferase and its in vivo stability. Hemin also interacts with
UBR1/UBR2. The terms “type 1” and “type 2” denote, respectively, the basic (Arg, Lys, and His) and bulky hydrophobic residues (Leu, Phe, Trp, Tyr, Ile, and
also Met, if the latter is followed by a bulky hydrophobic residue [V]). Type 1 and type 2 primary destabilizing Nt residues are recognized by distinct
substrate-binding sites of the pathway’s E3 N-recognins. The UBR1 and UBR2 E3 Ub ligases are sequelogous to each other and to S. cerevisiae UBR1.
Specific components of the human Arg/N-degron pathway have been shown to form a targeting complex (34). The S. cerevisiae Arg/N-degron pathway is
also mediated by an analogous multienzyme complex (34). A “generic” targeting complex of the mammalian Arg/N-degron pathway (red circle on the
Right) denotes a hypothetical set of analogous complexes. Only one of these complexes (containing UBR1 or UBR2 E3) was identified so far (34). Other,
analogous targeting complexes may contain, in particular, either UBR4 or UBR5 E3s. A targeting complex is likely to include the 26S proteasome as well
(34). The Ub-activating (E1) enzyme is expected to be a transient component of the complex, since E1 is a ligand of E2 enzyme. See Introduction for
additional references.
†
“Sequelog” denotes a sequence that is similar, to a specified extent, to another sequence
(39). Derivatives of sequelog include sequelogy (sequence similarity) and sequelogous
(similar in sequence). The usefulness of sequelog and derivative notations stems from the
rigor and clarity of their evolutionary neutrality. By contrast, in settings that use “ho-
molog,” “ortholog,” and “paralog” (they denote, respectively, common descent and
functional similarity/dissimilarity), these terms are often interpretation laden and impre-
cise. Homolog, ortholog, and paralog are compatible with the sequelog terminology.
The former terms can be used to convey understanding about common descent and
biological functions if this additional information, distinct from sequelogy per se, is ac-
tually present (39).
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Nt-Cys-sulfonate (Fig. 1). As a result, the Arg/N-degron pathway
functions as a sensor of oxygen/NO, through the conditional and
arginylation-dependent degradation of Nt-Cys-bearing tran-
scription factors and regulators of G proteins (13, 18, 28). Five
enzymes of the human Arg/N-degron pathway (UBR1 or UBR2
E3, UBE2A or UBE2B E2, ATE1 R-transferase, NTAN1 Asn/
Nt-amidase, and NTAQ1 Gln/Nt-amidase) form a targeting
complex (34) (Fig. 1). An analogous multienzyme complex me-
diates the S. cerevisiae Arg/N-degron pathway (34).
Homozygous inactivation of human hsUBR1 (with retention of
other E3 Arg/N-recognins; Fig. 1) causes a birth defect called
Johanson-Blizzard syndrome (JBS). Its symptoms include exo-
crine pancreatic insufficiency and inflammation, anatomical
malformations, mental retardation, and deafness (2, 40).
mmUBR1−/− mice have a milder version of JBS (40). Abnormal
phenotypes of mmUBR2−/− mice include infertility of males,
owing to apoptosis of mmUBR2−/− spermatocytes (2, 16). Mouse
(or human) UBR1 and UBR2 E3s are 47% identical and overlap
functionally (2, 15, 16). In contrast to viability of single-mutant
mmUBR1−/− and mmUBR2−/− mouse strains, mice that lack both
mmUBR1 and mmUBR2 die as midgestation embryos, with
massive neural and cardiovascular defects (41).
Our previous work described construction of conditional
double-knockout (2-KO) adult (mmUBR1−/− mmUBR2−/−) mice
and also unconditional 2-KO (hsUBR1−/− hsUBR2−/−) human
HEK293T cell lines that lacked both hsUBR1 and hsUBR2 (42).
Employing these tools, we identified ATF3, a stress-inducible
basic leucine zipper (bZIP) transcription factor (TF) that regu-
lates hundreds of genes, as a short-lived substrate of the Arg/
N-degron pathway (42).
In the present study, we used split-Ub protein-binding assays,
RNA-sequencing (RNA-seq), and quantitative mass spectrome-
try (MS) (42–45) to search for other TFs that interact with
hsUBR1/hsUBR2 and also to compare the levels of specific
mRNAs and proteins between wild-type human HEK293T cells
and their 2-KO (hsUBR1−/− hsUBR2−/−) mutants. The results
described here include identification of the glucocorticoid re-
ceptor (hsGR) TF and hsPREP1 TF as putative substrates of the
Arg/N-degron pathway, in part because both TFs interact with
hsUBR1. The levels of some mRNAs and proteins were found to
strongly differ between 2-KO and wild-type human cells. For
example, we observed ∼20-fold increases of specific mRNAs
(and encoded proteins) in 2-KO cells or an essentially complete
repression of other mRNAs (and encoded proteins) in 2-KO
cells. For instance, a TF called DACH1 and the main neuro-
filament subunits NF-L and NF-M were robustly expressed in
wild-type cells but were virtually absent in 2-KO cells. Tellingly, a
disappearance or near disappearance of some proteins in 2-KO
cells took place despite increases in the levels of their mRNAs,
strongly suggesting that the UBR1/UBR2-mediated Arg/
N-degron pathway can also modulate translation of specific
mRNAs. In sum, this multifunctional proteolytic system has
emerged as a regulator of mammalian gene expression, in part
through conditional targeting of TFs that include ATF3, GR,
and PREP1.
Results and Discussion
Human 2-KO (hsUBR1−/− hsUBR2−/−) HEK293T cell lines that
lacked both hsUBR1 and hsUBR2, two sequelogous (39) and
functionally overlapping E3 N-recognins (Fig. 1), were con-
structed and characterized in our preceding study (42). We de-
scribe here the use of 2-KO cells and other tools to identify
specific substrates and functions of this pathway.
RNA-Seq Analyses of Wild-Type Versus 2-KO (hsUBR1−/− hsUBR2−/−)
Human Cells.Genome-wide quantitative RNA-seq was carried out
with RNA preparations from wild-type and 2-KO human
HEK293T cells (Fig. 2 and SI Appendix, Figs. S2–S7). Our initial
aim was to determine whether the ablation of hsUBR1/hsUBR2
would cause not only moderate alterations of gene expression
but also significantly higher than twofold changes in the levels of
specific human mRNAs. If large effects in either direction would
be observed, we planned to verify them by independent methods.
A focus on strong changes stemmed from the expectation that a
major effect of ablating hsUBR1/hsUBR2 on the level of a
specific mRNA would facilitate the understanding of a link be-
tween that effect and the Arg/N-degron pathway.
Relative mRNA levels were the averages of three independent
RNA-seq measurements for wild-type and 2-KO HEK293T cell
lines. The scatter of RNA-seq data among three datasets (for
each of these cell lines), particularly for mRNAs whose levels
changed by more than twofold in either direction, was quite low
(<5%) (SI Appendix, Fig. S2). Some mRNAs analyzed by RNA-
seq were also quantified by 32P-Northern hybridization and/or
RT-qPCR. The results were in at least qualitative agreement
with RNA-seq data (Fig. 2 and SI Appendix, Figs. S2–S5). In
these measurements, a second, independently constructed 2-KO
HEK293T cell line, denoted as 2-KO #2, was also used as ad-
ditional control (Fig. 2 A, B, and E and SI Appendix, Fig. S3).
RNA-seq analyses (Fig. 2 and SI Appendix, Figs. S2, S4–S7)
quantified mRNA levels for ∼18,000 human genes. Among
them, 161 (<1%) genes exhibited at least twofold increases of
mRNAs in 2-KO cells. Conversely, 211 (<2%) genes were de-
creased by twofold or more (Fig. 2 and SI Appendix, Figs. S2 and
S5 A–C). We confined further analyses to genes for which the
maximal level of a specific mRNA, in either 2-KO or wild-type
cells, comprised at least 50 sequence “reads.” Each read is an
alignment of a sequenced, RNA-seq-detected segment of mRNA
to the reference human genome (SI Appendix, Figs. S6 and S7).
Consequently, the above 161 genes up-regulated by twofold or
higher became 39 genes, chosen for high-confidence (at least 50
sequence reads) increases of mRNA in 2-KO cells. Analogously,
the above 211 down-regulated genes became 93 genes, selected
for high-confidence twofold or stronger decreases of mRNA
levels in 2-KO cells (Fig. 2 and SI Appendix, Figs. S2–S7).
The 132 (39 + 93) altered-level mRNAs, that were chosen
using criteria described above for explicit citation, comprise a
high-confidence subset of all mRNAs whose levels were altered,
in either direction, between 2-KO and wild-type cells (Fig. 2 and
SI Appendix, Figs. S2–S7). SI Appendix, Fig. S4 cites 39 human
mRNAs whose levels were increased in 2-KO cells by at least
2-fold (from 22-fold to 2-fold). The fold values, measured by
RNA-seq and also for some mRNAs by 32P-Northerns and RT-
qPCRs, are shown in black, red, and green, respectively (SI
Appendix, Fig. S4). Descriptions of encoded proteins that are
TFs or components of the Ub system are in red and blue, re-
spectively (SI Appendix, Fig. S4). SI Appendix, Fig. S5 uses the
same notations, citing 93 mRNAs that were decreased by at least
2-fold (from ∼100-fold to 2.0-fold).
Up-Regulation of Specific Human mRNAs in 2-KO Cells. In the above
sets of mRNAs, our analyses concentrated on 10 up-regulated
and 10 down-regulated mRNAs for which the effects of ablating
hsUBR1/hsUBR2 were particularly strong (Fig. 2D). It should be
emphasized that alterations in the levels of other mRNAs, the
ones not cited in Fig. 2D (SI Appendix, Figs. S4 and S5), are also
worth exploring further, since many of these changes are likely to
be as significant functionally as the strongest effects.
In the 10-gene set of up-regulated mRNAs, two of them,
hsADRB2, encoding β-adrenergic receptor-2, and hsMCT2
(hsSLC16A7), encoding a monocarboxylate transporter, were
increased by 17-fold and 22-fold, respectively (Fig. 2 B and D and
SI Appendix, Fig. S4). In the former case, which was quantified
independently by 32P-Northerns, the detection of hsADRB2
mRNA in wild-type cells required a strong overexposure of
32P-autoradiograms (Fig. 2B, lanes 7 and 8; compare to lanes 4
31096 | www.pnas.org/cgi/doi/10.1073/pnas.2020124117 Vu et al.
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and 5). Four mRNAs, encoding hsLGALS3BP (it functions in
cell adhesion), hsPWWP3B (a protein of unknown function),
hsARMCX2 (a putative mitochondrial protein), and hsBARX1
(a TF that mediates craniofacial development and odonto-
genesis), were increased, in 2-KO cells, by 6.2-fold, 5.6-fold, 5.2-
fold, and 4.9-fold, respectively (Fig. 2D and SI Appendix, Figs.
S3A and S4).
In the 10-gene set of down-regulated mRNAs, 3 of them
encoding hsMAGEA6 (a regulator of Ub ligases), hsMAP7D2 (a
putative microtubule-binding protein), and hsLCP1 (an actin-
binding protein), were decreased by at least 50-fold, from ro-
bust expression in wild-type cells to undetectable or nearly un-
detectable levels in 2-KO cells (Fig. 2 D and E and SI Appendix,
Fig. S5A). mRNAs encoding hsSPINT2 (a peptidase inhibitor),
hsAFF2 (an RNA-binding protein), and hsSLC2A3 (a glucose
transporter) were decreased, in 2-KO cells, by 33-fold, 25-fold,
and 16-fold, respectively (Fig. 2D and SI Appendix, Figs. S5A
and S7).
hsADRB2 mRNA, Encoding β-Adrenergic Receptor-2, Is Increased by
17-Fold in 2-KO Cells. The mammalian ADRB2 β-adrenergic
receptor-2, a multispanning transmembrane protein, is
expressed in most tissues. ADRB2 recognizes catecholamines
(including epinephrine), is coupled to a subset of G proteins and
regulates in particular the levels of cyclo-AMP (cAMP) (46–48).
The 17-fold up-regulation of hsADRB2 mRNA in 2-KO cells was
accompanied by a robust expression of hsADRB2 protein in
these cells, as indicated by immunoblotting (IB) with antibody to
hsADRB2 (Fig. 2 B–D and SI Appendix, Fig. S4). In contrast,
hsADRB2 was undetectable by IB in wild-type cells, in agree-
ment with near-zero levels of hsADRB2 mRNA in those cells
(Fig. 2B).
Comparisons of Transcriptional Promoters to Address Overexpression
of hsADRB2 in 2-KO Cells. The hsADRB1 gene, encoding
β-adrenergic receptor-1, was not up-regulated in 2-KO
(hsUBR1−/− hsUBR2−/−) HEK293T cells, in contrast to
hsADRB2, which encodes a protein highly sequelogous to
hsADRB1 (Fig. 2 B–D and SI Appendix, Figs. S3 and S4). (Levels
of hsADRB1 mRNA were too low for detection by RNA-seq in
both 2-KO and wild-type cells.) While the 17-fold increase of
hsADRB2 mRNA in 2-KO cells (Fig. 2D and SI Appendix, Fig.
S4) might result in part from a metabolic stabilization of this
mRNA, a parsimonious interpretation is that at least the bulk of
this increase is caused by transcriptional induction of hsADRB2
in the absence of hsUBR1/hsUBR2.
For reasons that include large DNA spans and complexity of
mammalian transcriptional control, our comparisons of
hsADRB2 and hsADRB1 promoters were confined to ∼2-kb
DNA segments upstream of transcription start sites. Our aim
was to identify experimentally tractable differences in the pat-
terns of specific TF-binding sites between these promoters, with
the possibility of expanding, later, a search for differences be-
yond initially examined DNA segments (SI Appendix, Fig. S8).
hsADRB1 and hsADRB2 have been previously mapped using
expression assays, mutagenesis, gel-shift DNA binding, and other
methods (47, 48). hsADRB1 and hsADRB2 promoters contain
binding sites for a number of TFs, including hsNF-κB, hsAP2,
Fig. 2. Summary of RNA-seq and related analyses of wild-type (wt) vs. 2-KO (hsUBR1−/− hsUBR2−/−) human HEK293T cells. (A) IB analyses of the wild-type
(parental) HEK293T cell line and two independently produced 2-KO cell lines, #1 and #2, using anti-hsUBR1 and anti-hsUBR2 antibodies. (B) Lanes 1 through 3,
fractionated total RNA, stained with ethidium bromide, from wild-type HEK293T cells and 2-KO cell lines #1 and #2. The bands of 18S and 28S rRNAs are
indicated on the Left. Lanes 4 through 6, Northern hybridization, using a 32P-labeled RNA probe specific for the ∼2.1-kb hsADRB2 mRNA, of blotted RNAs in
lanes 1 through 3. Lanes 7 and 8, same as lanes 4 and 5, but a 7-fold longer autoradiographic exposure to detect hsADRB2 mRNA in wild-type cells (lane 7).
Lanes 9 through 11, same as lanes 4 through 6, but hybridization with a 32P-labeled RNA probe specific for the ∼1.3-kb hsGAPDH mRNA (loading control). (C)
Lanes 1 and 2, IB-based (using anti-hsADRB2 antibody) CHX chase, for 0 and 4 h, of hsADRB2 in wild-type HEK293T cells. Lanes 3 and 4, same as lanes 1 and 2,
but with 2-KO cell line #1, in which hsADRB2 mRNA was up-regulated by 17-fold (see B and the main text). (D) The list of 10 human mRNAs that were up-
regulated by at least 3.1-fold (from 22-fold to 3.1-fold) in 2-KO cell line #1, and the analogous list of 10 mRNAs that were down-regulated by at least 4.3-fold
(from more than 100-fold to 4.3-fold) in the above 2-KO cells. Superscript "a" in the right column denotes a minimal estimate of the extent of observed
repression. (E) 32P-Northern analysis (see B) of the repression of hsMAGE6 mRNA (see D) in 2-KO cell lines #1 and #2 (lanes 2 and 3) vs. robust expression of
hsMAGE6 in wild-type cells (lane 1).
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and hsSP1. Most of these and other TF-binding sites are shared
between hsADRB1 and hsADRB2. Nevertheless, we detected two
possible (nonalternative) causes of “up-regulation” difference
between these otherwise similar genes.
First, hsADRB2 promoter contains two sites that can bind to
hsSP1, an activator TF that up-regulates many genes (SI Ap-
pendix, Fig. S8) (49). In contrast, the analogous region of
hsADRB1 contains one hsSP1-binding site (SI Appendix, Fig. S8).
Second, the single hsSP1-binding site in hsADRB1 overlaps with
a site recognized by hsEGR1, a transcriptional repressor (47, 48).
Thus, interactions of hsSP1 and hsEGR1 TFs with hsADRB1
promoter are likely to be mutually exclusive (SI Appendix, Fig.
S8). Significantly, the hsADRB2 promoter lacks a binding site for
the hsEGR1 repressor, in contrast to hsADRB1. Finally, the
hsEGR1 repressor may be, at least in part, a substrate of the Arg/
N-degron pathway; this remains to be verified. If so, hsEGR1
would be up-regulated in 2-KO cells and would act to inhibit
transcription of hsADRB1, but not of hsADRB2. This mecha-
nistically specific and testable model (SI Appendix, Fig. S8) is
ready to be verified in future experiments.
hsMCT2mRNA, Encoding a Monocarboxylate Transporter, Is Increased
by 22-Fold in 2-KO Cells. hsMCT2 (hsSLC16A7) is a proton-linked
transporter of monocarboxylates such as lactate, pyruvate, and
ketone bodies (50, 51). hsMCT2 mRNA was increased by 22-fold
in 2-KO cells, as discovered by RNA-seq and confirmed by RT-
qPCR (the latter method suggested an even higher, 35-fold in-
crease of hsMCT2 mRNA in 2-KO cells) (Fig. 2D and SI Ap-
pendix, Fig. S4). The family of mammalian SLC16 (MCT)
transporters comprises 14 proteins. Substrates and partial func-
tions are known for only seven of these transporters (50, 51).
Mammalian MCT2 is expressed in most tissues and can mediate
either influx or efflux of its substrates, depending on substrate
levels and a pH gradient across a membrane (either the plasma
membrane or specific intracellular membranes). Functions of
MCT2 include lactate transport, particularly in the brain and
skeletal muscle (50).
In contrast to hsMCT2 mRNA, which was increased by 22-fold
in 2-KO cells (Fig. 2D and SI Appendix, Fig. S4), RNA-seq did
not detect mRNAs of 11 hsSLC16-family genes in either wild-
type or 2-KO cells. Two hsSLC16 family members other than
hsMCT2, specifically hsMCT1 (hsSLC16A7) and hsMCT8
(hsSLC16A2) mRNAs, were increased by 1.1-fold and 1.4-fold,
respectively, in 2-KO cells. Furthermore, MS-based protein
analyses (see below) of 2-KO cell lines #1 and #2 vs. wild-type
cells indicated, respectively, 2.4-fold and 4-fold decreases of the
hsMCT8 protein in 2-KO cells (SI Appendix, Fig. S12B), a di-
rection of changes that is opposite to 22-fold induction of
hsMCT2 mRNA (Fig. 2D) and up-regulation of hsMCT2 protein
(see below).
The selective and massive up-regulation of hsMCT2 mRNA
upon the ablation of hsUBR1/hsUBR2 (Fig. 2D and SI Appendix,
Fig. S4) opens up the same strategy of comparing transcriptional
promoters that yielded a verifiable model of selective up-
regulation of the hsADRB2 gene in 2-KO cells (SI Appendix,
Fig. S8). Analogous promoter comparisons are also possible with
other genes that are up-regulated or down-regulated in 2-KO
cells (Fig. 2D). In the present paper, such comparisons are
confined to hsADRB2 vs. hsADRB1 (SI Appendix, Fig. S8),
inasmuch as verifications of resulting models are still in the
future.
Double-KO HEK293T Cells, Which Overexpress hsMCT2 mRNA, Are
Hypersensitive to Dimethyloxalylglycine. MS-based protein analy-
ses (see below) confirmed an up-regulation of hsMCT2 protein
in 2-KO cells, with, respectively, 6.0-fold and 2.7-fold increases
of hsMCT2 in 2-KO cell lines #1 and #2 (SI Appendix, Fig.
S12A).
To address this question in a different way, we asked whether
the 22-fold increase of hsMCT2 mRNA in 2-KO cells (Fig. 2D
and SI Appendix, Fig. S4) and the resulting increase of encoded
protein cause a phenotype that can be traced to the level of
hsMCT2. The metabolite α-ketoglutarate (αKG) is a cosubstrate
(together with oxygen) of αKG-dependent dioxygenases (αKGDDs),
a family of enzymes that include prolyl hydroxylases (PHDs). The
oxygen-dependent hydroxylation by PHDs of specific Pro residues
in, for example, HIFα TF (which mediates responses to oxygen),
activates its degron and thereby regulates, through oxygen-modulated
degradation of HIFα, the expression of genes controlled by HIFα
(52, 53).
N-oxalylglycine (NOG), a synthetic analog of αKG, is a cyto-
toxic inhibitor of αKGDD enzymes, but NOG cannot enter cells
(51). Dimethyloxalylglycine (DMOG), a derivative of NOG, is
rapidly hydrolyzed in aqueous solutions to methyloxalylglycine
(MOG). Upon its entry into cells, MOG is converted to NOG.
The import of MOG is mediated largely by the MCT2 trans-
porter (51). Consequently, an up-regulation of hsMCT2 in 2-KO
cells would predict their hypersensitivity to extracellular DMOG,
in comparison to wild-type cells.
To compare sensitivities of cells to DMOG, we used a cell
mass accumulation assay (51). In the absence of DMOG, 2-KO
cell cultures grew at rates similar to those of parental
HEK293T cells (SI Appendix, Fig. S9A). In contrast, prolifera-
tion of 2-KO cells was found to be at least 5.4-fold more sensitive
to DMOG than proliferation of wild-type cells (SI Appendix, Fig.
S9B). “At least” refers to the fact that parameters of the cell
accumulation assay were not varied to maximize the measured
difference in sensitivity to DMOG between two cell lines.
These results (SI Appendix, Fig. S9), together with previous
demonstration that hsMCT2 is the main MOG importer (51),
confirm the above prediction that 2-KO cells, which overexpress
both hsMCT2 mRNA and the encoded protein (Fig. 2D and SI
Appendix, Figs. S4 and S11A), would be hypersensitive to growth
suppression by DMOG (specifically by NOG, which DMOG is
converted to, via MOG).
Other Genes That Are Up-Regulated in 2-KO Cells. In addition to
hsADRB2 and hsMCT2 mRNAs (increased by 17-fold and
22-fold, respectively), several other mRNAs (hsLGALS3BP,
hsPWWP3B, hsARMCX2, and hsBARX1) were also up-regulated
by more than 4-fold in 2-KO cells (Fig. 2D and SI Appendix, Fig.
S4). hsLGALS3BP is a protein that promotes cell adhesion
(https://www.uniprot.org/uniprot/Q08380). hsPWWP3B is a
broadly expressed protein of unknown function (https://www.
uniprot.org/uniprot/Q5H9M0) (Fig. 2D and SI Appendix, Fig.
S4). hsARMCX2 is a largely uncharacterized protein (https://
www.uniprot.org/uniprot/Q7L311) (Fig. 2D and SI Appendix, Fig.
S4). hsBARX1 is a homeodomain TF that is important for de-
velopment of craniofacial bones, teeth, cartilage, muscle, spleen,
stomach, and esophagus (54). The increase of hsBARX1 mRNA
in 2-KO HEK293T cells (4.9-fold by RNA-seq; 7.3-fold by RT-
qPCR) (Fig. 2D and SI Appendix, Figs. S3A and S4) may be
caused by a decreased degradation, in the absence of hsUBR1/
hsUBR2, of an unknown activator TF whose stabilization ac-
celerates transcription of hsBARX1. A nonalternative possibility
is that hsBARX1 TF is a positive regulator of its own gene and a
short-lived substrate of the Arg/N-degron pathway.
Repression of Specific Genes in 2-KO Cells. hsMAGEA6 is a member
of the family of human MAGE genes. Some MAGE proteins,
including hsMAGEA6, are components and modulators of spe-
cific Ub ligases. MAGE genes, including hsMAGEA6, are often
ectopically expressed in cancer cells, in which specific MAGEs
can act as oncogenic drivers (55). We found that hsMAGEA6
mRNA was expressed in wild-type cells, but was decreased by at
least 100-fold, i.e., was in effect shut off in 2-KO cells (Fig. 2 D
31098 | www.pnas.org/cgi/doi/10.1073/pnas.2020124117 Vu et al.
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and E and SI Appendix, Fig. S5A). hsLCP1 mRNA, which en-
codes an actin-binding protein (https://www.uniprot.org/uniprot/
P13796), was decreased, in 2-KO cells by at least 50-fold to <2%
of its level in wild-type cells (Fig. 2D and SI Appendix, Fig. S5A).
hsSLC2A3 mRNA, which encodes a glucose transporter (https://
www.uniprot.org/uniprot/P11169), was decreased in 2-KO cells
to <6% of its level in wild-type cells (Fig. 2D and SI Appendix,
Fig. S5A).
Mass Spectrometric Analyses of Proteins in Wild-Type and 2-KO
HEK293T Cells. MS-based protein surveys employed the quantita-
tive TMT-SPS-MS3 (targeted mass tags-based sample
multiplexing-mass spectrometric-3) technique (45) and were
carried out with protein preparations from wild-type vs. 2-KO
HEK293T cells (SI Appendix, Fig. S10). The TMT-SPS-MS3
method is summarized in SI Appendix, Fig. S11. TMT-SPS-MS3
analyses of wild-type and two 2-KO cell lines (#1 and #2)
encompassed 83,513 peptides and corresponded to 7,714 dif-
ferent human proteins. Cited below are the main MS-based re-
sults:
1) A total of 45 proteins were found to be up-regulated, relative
to wild-type HEK293T cells, by at least 2-fold in the 2-KO #1
cell line. In most (though not all) cases, these proteins were
also classed as up-regulated in the 2-KO cell line #2 (SI
Appendix, Fig. S12 A and B).
2) A total of 111 proteins were found to be down-regulated
relative to wild-type cells by at least 2-fold in 2-KO cells
(Fig. 3 and SI Appendix, Fig. S13 A–D).
3) The above proteins (156 = 45 + 111), whose levels were
significantly increased or decreased in 2-KO HEK293T cells,
relative to wild-type cells, encompassed a vast range of func-
tions or putative functions (SI Appendix, Figs. S12 A and B
and S13 A–D).
4) Changes in levels of the above 156 proteins (156 = 45 + 111)
in 2-KO cells, as determined by MS analyses, will be gradu-
ally verified in future studies by independent methods, in-
cluding quantitative IB. Verifications were initiated here
with three proteins, hsDACH1, hsNF-L (hsNFEL), and
hsNF-M (hsNFEM). According to MS, these proteins were
down-regulated, respectively, by ∼5-fold, ∼16-fold, and ∼16-
fold, in 2-KO cells, relative to wild-type cells (SI Appendix,
Fig. S13A).
Using IB, we confirmed these findings (Fig. 3). Moreover, IB
analyses showed that these endogenous, untagged proteins, while
robustly expressed in wild-type HEK293T cells, either dis-
appeared or nearly disappeared in 2-KO cell lines #1 and #2
(Fig. 3). Thus, the extents of repression of these three proteins in
2-KO cells that were measured by quantitative IB were even
greater than MS-suggested repression levels (Fig. 3 and SI Ap-
pendix, Fig. S13A; see also below). These findings suggest that
MS analyses, while invaluable for discovering specific proteins
that are down-regulated in 2-KO cells (SI Appendix, Fig.
S13 A–D), may underestimate the extents of their repression.
This circumstance encourages future analyses of MS-identified
proteins that are down-regulated in 2-KO cells (SI Appendix, Fig.
S12 A–D) using independent methods, including quantitative IB.
Described below are our first IB results with hsDACH1, hsNF-L,
and hsNF-M.
Near Disappearance of the hsDACH1 Transcription Factor in 2-KO
Cells. The 758-residue hsDACH1 is a TF whose functions in-
clude tumor suppression and regulation of organogenesis (56).
According to TMT-SPS-MS3 data, the levels of hsDACH1
protein in 2-KO cells, in comparison to wild-type cells, were
decreased by ∼5-fold and ∼3-fold, respectively, in 2-KO cell lines
#1 and #2 (SI Appendix, Fig. S13A).
IB analyses of endogenous, untagged hsDACH1 using anti-
hsDACH1 antibody and chemiluminescence-based IB showed
a robust expression of hsDACH1 in wild-type HEK293T cells
and an even stronger (more than 10-fold) repression of the
hsDACH1 protein in 2-KO #1 and #2 cell lines than the extent
of down-regulation estimated by MS (Fig. 3A and SI Appendix,
Fig. S13A). Detection of proteins by IB using chemiluminescence
is more sensitive than quantitative detection using near-infrared
fluorescence dyes and an Odyssey-type scanner, but the former
method is at best semiquantitative, hence the above minimal
estimate rather than a measurement. With a near-infrared
quantitative system, detection of hsDACH1 in 2-KO cells
would have been impossible without a strong sample overload.
Possible causes of the near disappearance of hsDACH1 in 2-KO
cells (Fig. 3A) are mentioned below.
Near Disappearance of the Neurofilament Subunits NF-M and NF-L in
2-KO Cells. Neurofilaments are a specific class of intracellular
intermediate filaments. Four main subunits of mammalian neu-
rofilaments are NF-L (encoded by NFEL), NF-M (encoded by
NFEM), NF-H (encoded by NFEH), and either α-internexin
(encoded by INA) or peripherin (encoded by PRPH) (57, 58).
Neurofilaments are present largely in neurons. Most HEK293T
(and related) cell lines (which were produced by transformation
of primary cultures of human embryonic kidney [HEK] cells with
fragments of adenoviral DNA) contain neurofilaments and ex-
press their subunits, suggesting that HEK cell lines are actually
of neuronal origin (59). Our wild-type HEK293T cells contained
at least the NF-L, NF-M, and α-internexin subunits (Fig. 3B,
lanes 1 and 2; Fig. 3 C and E, lanes 1 and 4, and SI Appendix,
Figs. S12A and S13A).
In neurons, neurofilaments are present in both perikarya and
dendrites and are particularly abundant in axons, in which they
play major roles. Neurofilaments are regulated by phosphoryla-
tion and other modifications, and interact with a number of in-
tracellular proteins. Abnormal accumulations of neurofilaments
are characteristic of many diseases, including amyotrophic lateral
sclerosis, Charcot-Marie-Tooth disease, neurofilament inclusion
disease, giant axonal neuropathy, spinal muscular atrophy, and
both Alzheimer’s and Parkinson’s diseases. Aberrant overpro-
duction of neurofilaments in these diseases apparently contrib-
utes in major ways to the death of affected neurons (57, 58).
According to MS, the levels of hsNF-M protein were de-
creased by ∼16-fold in both 2-KO cell lines, #1 and #2, relative
to wild-type cells (SI Appendix, Fig. S13A). IB analyses (using
anti-hsNF-M antibody) confirmed these results. Moreover, the
endogenous, untagged hsNF-M protein, while robustly expressed
in wild-type HEK293T cells, was nearly undetectable by IB in
both 2-KO cell lines, suggesting an even greater than ∼16-fold
repression of hsNF-M in 2-KO cells (Fig. 3B and SI Appendix,
Fig. S13A). Cycloheximide (CHX) chases of hsNF-M indicated
its stability over 4 h in wild-type cells (Fig. 3B), in agreement with
earlier findings (57, 58).
Similar results were obtained with hsNF-L, another neuro-
filament subunit, which binds to hsNF-M. According to MS, the
level of hsNF-L was decreased, respectively, by ∼16-fold and
∼20-fold in 2-KO cell lines #1 and #2, relative to wild-type cells
(SI Appendix, Fig. S13A). IB analyses of hsNF-L (using anti-
hsNF-L antibody) employed both the quantitative Odyssey IB
system and chemiluminescence-based IB. These and other IB
assays also used antibody to glyceraldehyde 3-phosphate dehy-
drogenase (hsGAPDH) to detect hsGAPDH as a loading control
(Fig. 3 C–E).
IBs detected expression of the endogenous, untagged hsNF-L
protein in wild-type HEK293T cells and also indicated a com-
plete or nearly complete disappearance of hsNF-L in both 2-KO
cell lines (Fig. 3 C–E). Quantification using the Odyssey system
of the repression of hsNF-L in 2-KO cells yielded an ∼40-fold
Vu et al. PNAS | December 8, 2020 | vol. 117 | no. 49 | 31099
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difference between the levels of hsNF-L in wild-type vs. 2-KO
cells (Fig. 3 C and D; see also Fig. 3E). Thus, IB assays indicated
an even stronger down-regulation of hsNF-L than the one sug-
gested by MS data (SI Appendix, Fig. S13A).
In sum, the expression of hsNF-L and hsNF-M proteins was
nearly completely abolished in 2-KO human cells, in contrast to
robust expression of these proteins in wild-type cells (Fig. 3 B–E
and SI Appendix, Fig. S13A). α-Internexin (encoded by hsINA) is
present in some but not all neurofilaments. In contrast to hsNF-
L and hsNF-M, α-internexin was increased by approximately
twofold in 2-KO cells (SI Appendix, Fig. S12A). Thus, the nearly
complete dependence of expression of hsNF-L and hsNF-M on
the presence of hsUBR1/hsUBR2 (Fig. 3 B–E and SI Appendix,
Fig. S13A) does not encompass all subunits of neurofilaments.
Repression in 2-KO Cells of NF-L and NF-M Takes Place Despite
Up-Regulation of Their mRNAs. Remarkably, the disappearance
or near disappearance of hsNF-L and hsNF-M in 2-KO cells (in
contrast to their robust expression in wild-type cells) took place
despite up-regulation by ∼1.7-fold and ∼1.2-fold, respectively, of
hsNF-L (hsNFEL) and hsNF-M (hsNFEM) mRNAs in 2-KO
cells (Fig. 3 B–E and SI Appendix, Fig. S13A). Thus, the near
absence of hsNF-L and hsNF-M proteins in 2-KO cells could not
have been caused by transcriptional repression of the corre-
sponding genes or by destabilization of hsNF-L and hsNF-
M mRNAs.
A parsimonious interpretation of these results is that the ab-
sence of the hsUBR1/hsUBR2 Ub ligases causes repression of
translation of hsNF-L and hsNF-M mRNAs in 2-KO cells. In one
verifiable model, a selective translational repression would be
caused by metabolic stabilization (and therefore up-regulation)
of a normally short-lived (and remaining to be identified)
translational repressor(s) of hsNF-L and hsNF-M mRNAs in
2-KO cells. The postulated repressor(s), presumably an RNA-
binding protein(s) that recognizes hsNF-L and hsNF-M mRNAs,
is normally down-regulated through degradation by the hsUBR1/
hsUBR2-mediated Arg/N-degron pathway. Consequently, this
repressor(s) becomes long-lived in 2-KO cells, and its level in-
creases strongly enough to shut off translation of (at least) hsNF-
L and hsNF-M mRNAs. Work to verify this model is under way.
In contrast to hsNF-L and hsNF-M proteins, whose near dis-
appearance in 2-KO cells takes place despite up-regulation of
Fig. 3. Immunoblot analyses of proteins whose down-regulation in 2-KO (hsUBR1−/− hsUBR2−/−) human HEK293T cells was initially detected by MS. Unless
stated otherwise, cells were grown in the presence of fetal bovine serum (FBS). Detection of bound antibodies was performed using chemiluminescence (in A,
B, and E) or near-infrared fluorescence and an Odyssey-type scanner (in C and D). (A) Lanes 1 and 2, IB-based CHX chase (using anti-hsDACH1 antibody) for
0 and 4 h of hsDACH1 TF in extracts from wild-type HEK293T cells. Lanes 3 and 4, same as lanes 1 and 2, but with 2-KO cell line #1. Lanes 5 and 6, same as in
lanes 3 and 4, but with 2-KO cell line #2. Blue stars, in this and other panels, indicate positions of molecular mass markers. Black asterisk indicates a cross-
reacting protein. (B) Same as in A, but with the hsNF-M subunit of neurofilaments, using anti-hsNF-M antibody. The apparent (anomalous) Mr (molecular
mass), upon sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/PAGE), of the 916-residue hsNF-M is ∼150 kDa. (C) Lanes 1 through 3, IB analyses
of hsNF-L, using anti-hsNF-L antibody, in wild-type HEK293T cells, 2-KO cell line #1, and 2-KO cell line #2. The apparent Mr, upon SDS/PAGE, of the 543-residue
hsNF-L is ∼70 kDa. Lanes 4 through 6, same as in lanes 1 through 3, but using extracts from cells preincubated in the absence of FBS. (D) Same as in C but IB
with anti-hsGAPDH antibody (loading control). (E) Same as in C but detection of hsNF-L using anti-hsNF-L antibody and chemiluminescence.
31100 | www.pnas.org/cgi/doi/10.1073/pnas.2020124117 Vu et al.
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their respective mRNAs in these cells (Fig. 3 B–E and SI Ap-
pendix, Fig. S13A), the near absence of hsDACH1 TF in 2-KO
cells is accompanied by a 3.8-fold decrease of its mRNA (Fig. 3A
and SI Appendix, Fig. S13A). Nevertheless, the observed down-
regulation of hsDACH1 protein in 2-KO cells is much stronger
than the down-regulation of hsDACH1 mRNA, suggesting that
an hsUBR1/hsUBR2-dependent translational repression, de-
scribed in the context of hsNF-L and hsNF-M proteins, may also
apply, at least in part, to regulation of hsDACH1.
Split-Ubiquitin Binding Assays. In this technique, two proteins are
expressed in yeast as fusions to a Ct-half of Ub (CUb) and to its
mutant Nt-half (NUb), respectively (Fig. 4A) (43, 60). An inter-
action between two examined proteins (which contain linked Ub
halves) would reconstitute a Ub moiety from CUb and mutant
NUb. Consequently, a CUb-containing test fusion would be
cleaved by deubiquitylases at the last (Gly) residue of the
reconstituted Ub moiety. This cleavage acts, through additional
steps, as a set of assay’s readouts (Fig. 4A) (43). They comprise,
in particular, an induction of scHIS3 and scADE2 genes
(Fig. 4A), thereby making possible growth assays on media that
lack either histidine (His) or both His and adenine (Ade)
(Fig. 4). Control experiments included IBs to examine expression
of split-Ub fusions and also verification of the absence of
autoactivation, i.e., that binding-positive fusions did not remain
positive in split-Ub assays with just one of two fusions. The re-
sults described below passed all of these controls.
Having previously detected, in part through split-Ub assays,
the binding of the stress-inducible bZIP-class hsATF3 TF to an
Nt-fragment of hsUBR1 (42), we examined here hsUBR1 in-
teractions with two other TFs, the hsPREP1 TF and the gluco-
corticoid receptor (hsGR) TF, encoded by the hsNR3C1 gene
(Fig. 4). We tested hsPREP1 (hsPKNOX1), a homeodomain TF
(61) (Fig. 4B), owing to a significant sequelogy between
hsPREP1 and S. cerevisiae scCUP9, a yeast transcriptional re-
pressor. scCUP9 is a key part of a circuit in which the conditional
(regulated by short peptides) degradation of scCUP9 by the Arg/
N-degron pathway controls the rate of peptide import in yeast
(see below) (2, 35, 36).
hsGR, a zinc-finger TF, is modulated by glucocorticoids and
regulates processes that include immune responses as well as cell
growth and differentiation (62). We tested hsGR for its binding
to hsUBR1 (Fig. 4C) owing, in part, to MS-based data that the
hsGR protein was up-regulated by 1.5-fold and 2.0-fold, re-
spectively, in 2-KO cell lines #1 and #2, relative to wild-type
cells. In addition, hsGR mRNA was up-regulated by 1.4-fold in
2-KO cell line #1, according to RNA-seq. These results are not
mentioned in the corresponding protein and mRNA lists (SI
Appendix, Figs. S4 and S12), inasmuch as the cited protein in-
creases had been “ordered” according to data with 2-KO cell line
#1 and had to be 2-fold or higher to make it into the list. We
found later that hsGR protein is up-regulated by significantly
more than 2-fold in 2-KO cells, in agreement with physical
binding of an isoform of hsGR to an Nt-half of hsUBR1, as
described below (Figs. 4C and 5).
hsPREP1 Transcription Factor Binds to the N-Terminal Fragment of
hsUBR1 but Not to Full-Length hsUBR1. Split-Ub assays revealed
the binding of hsUBR11−1059, the 123-kDa Nt-fragment of the
200 kDa hsUBR1 E3, to the full-length 48-kDa hsPREP1
(Fig. 4B, row 2). In contrast, hsPREP1 did not bind to either full-
length hsUBR1 or its 77-kDa Ct fragment (hsUBR11060−1749)
(Fig. 4B, rows 1 through 4). The binding of a physiological
substrate of UBR1 to its Nt-fragment but not to full-length
UBR1 has been encountered earlier in two different settings.
First, hsATF3, a bZIP TF, was found to interact, both in split-
Ub assay and in another (conceptually different) binding assay,
with the Nt-fragment of hsUBR1 but not with its full-length
counterpart (42). Second, S. cerevisiae scCUP9 TF, a transcrip-
tional repressor of a regulon that includes the scPTR2 peptide
importer, was found to bind, unconditionally, to the analogous
Nt-fragment of scUBR1, but would bind to full-length scUBR1
only in the presence of dipeptides bearing destabilizing (type-1/
2) Nt-residues (2, 35, 36). As shown previously, Nt-residues of
such dipeptides can interact with two cognate-binding sites of
full-length scUBR1 (they are present in hsUBR1 as well; Fig. 1),
thereby altering conformation of scUBR1 and enabling its
binding to the scCUP9 repressor, followed by polyubiquitylation
Fig. 4. Split-ubiquitin binding assays with transcription factors hsPREP1 and
glucocorticoid receptor (hsGR) vs. hsUBR1 E3 ubiquitin ligase. (A) Design of
split-Ub assays (also see the main text). (B) Row 1, hsPREP1 vs. full-length
hsUBR1. Row 2, hsPREP1 vs. Nt-fragment of hsUBR1 (hsUBR11−1059). Row 3,
hsPREP1 vs. Ct-fragment of hsUBR1 (hsUBR11060−1749). Row 4, hsPREP1 vs.
vector alone. Note the binding of hsPREP1 solely to the Nt-fragment of
hsUBR1. (C) See the main text and Fig. 5 for definitions and descriptions of
the hsGR-D isoform. Row 1, hsGR-D vs. full-length hsUBR1. Row 2, hsGR-D vs.
Nt-fragment of hsUBR1 (hsUBR11−1059). Row 3, hsGR-D vs. Ct-fragment of
hsUBR1 (hsUBR11060−1749). Row 4, hsGR-D vs. vector alone. Row 5, hsGR-A vs.
full-length hsUBR1. Row 6, hsGR-A vs. Nt-fragment of hsUBR1
(hsUBR11−1059). Row 7, hsGR-A vs. Ct-fragment of hsUBR1 (hsUBR11060−1749).
Row 8, hsGR-A vs. vector alone.
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and degradation of scCUP9 (36). The resulting proteolysis-based
scUBR1-scCUP9-scPTR2 circuit, regulated by short peptides,
enables yeast cells to “sense” extracellular peptides and to ac-
celerate their uptake (2, 35, 36). Despite physiologically plausi-
ble analogies between the conditional binding of scCUP9 to full-
length scUBR1 and the current disposition with human hsATF3
and hsPREP1 (and with hsGR as well; see below), our binding
assays did not suggest, so far, any “induction,” by short peptides,
of interactions between full-length hsUBR1 and either hsATF3
or hsPREP1, which bind to the Nt-fragment of hsUBR1 but not
to its full-length counterpart (Fig. 4B).
Isoform D of Glucocorticoid Receptor TF Binds to the N-Terminal
Fragment of hsUBR1 but Not to Full-Length hsUBR1. Human hsGR,
encoded by hsNR3C1 and described above, exists in cells as a set
of protein isoforms that include the major and largest (94 kDa)
isoform hsGR-A, as well as smaller isoforms, including the
54 kDa hsGR-D (Fig. 5A). hsGR-A comprises the Nt domain,
DNA-binding domain, hinge region, and the ligand-binding
(glucocorticoid binding) domain (LBD) (Fig. 5A) (62).
Split-Ub assays revealed the binding of the Nt-fragment of
hsUBR1 (hsUBR11−1059) to the smallest, 54-kDa isoform hsGR-
D (Fig. 4C, row 2, and Fig. 5A). However, similarly to hsATF3
and hsPREP1 TFs, the hsGR-D did not bind to full-length
hsUBR1 (Fig. 4C, rows 1 through 4). In addition and remark-
ably, the largest isoform, hsGR-A, despite encompassing the
entire hsGR-D isoform (Fig. 5A), did not bind to either full-
length hsUBR1 or its fragments (Fig. 4C, rows 5 through 8;
compare with rows 1 through 4). Thus, the interaction, under the
conditions of split-Ub assays, between hsGR and hsUBR1 was
“restricted” for both ligands, in that the binding occurred solely
between the Nt-fragment of hsUBR1 and the hsGR-D isoform,
but was not observed (for any form of hsUBR1) with the largest
isoform, hsGR-A (Figs. 4C and 5A).
Up-Regulation of Glucocorticoid Receptor in 2-KO Cells. Cyclohexi-
mide (CHX)-based chase-degradation assays with untagged,
endogenous hsGR used IB assays, anti-hsGR antibody, and wild-
type HEK293T cells vs. 2-KO cells (Fig. 5). hsGR-A, the largest
hsGR isoform, was largely stable during 6-h CHX chase, but
became unstable in the presence of geldanamycin (GA), an in-
hibitor of the HSP90 chaperone (Fig. 5B, lanes 1 through 6). The
latter finding was in agreement with hsGR being a client of
HSP90, which assists the folding of hsGR and partially protects it
from degradation (62). Remarkably, the steady-state levels of
endogenous hsGR-A were at least 5-fold higher in both 2-KO
cell lines, #1 and #2, than in wild-type cells (Fig. 5B, lanes 7
through 18; compare with lanes 1 through 6).
In addition, a higher-sensitivity detection (a longer chem-
iluminescence exposure) revealed, in 2-KO cell lines, a greatly
increased level of hsGR-D, the smallest hsGR isoform (Fig. 5C),
the one that has been found, above, to interact with the Nt-half
of hsUBR1 (Fig. 4C). While undetectable in wild-type
HEK293T cells even at the highest sensitivity of IB assays
(Fig. 5C, lanes 1 through 6), the hsGR-D isoform was readily
detectable and stable during a 6-h chase in the 2-KO cell line #1
(Fig. 5C, lanes 7 through 9), while being also up-regulated
but less stable in the 2-KO cell line #2 (Fig. 5C, lanes 13
through 15).
Interestingly, the hsGR-D isoform became short-lived, in both
2-KO cell lines, in the presence of GA, despite the absence in
these cells of both the hsUBR1 and hsUBR2 Ub ligases (Fig. 5C,
lanes 10 through 12 and 16 through 18). Thus, the bulk of the
Arg/N-degron pathway (its hsUBR1/hsUBR2 part) is not re-
quired for the degradation of either hsGR-A or hsGR-D iso-
forms (the latter isoform binds to the Nt-fragment of hsUBR1)
that lost their protection by the HSP90 chaperone, in agreement
with the known targeting of many specific TFs by more than one
proteolytic pathway (63).
A parsimonious but not the only possible interpretation of
these results is that the strong increase of both hsGR-A and
hsGR-D isoforms (and other, “intermediate” hsGR isoforms as
well) in 2-KO HEK293T cells (Fig. 5C) stems, at least in part,
from a metabolic stabilization of these isoforms in the absence of
hsUBR1/hsUBR2. The apparent stabilization of the hsGR-D
isoform in this genetic background (Fig. 5C, lanes 7 through 9)
suggests that the relevant (hsUBR1/hsUBR2 targeted) degron of
hsGR resides in its LBD, which occupies the bulk of hsGR-D
isoform (Fig. 5A).
In this interpretation, the largest (hsGR-A) isoform, the one
that did not bind to any form of hsUBR1, in contrast to the
hsGR-D isoform (Fig. 4C), is nevertheless recognized and
destroyed by the Arg/N-degron pathway in vivo, in wild-type
cells, similarly to hsGR-D. If so, a specific reason for the re-
producible absence of binding of hsGR-A to any form of
hsUBR1 in split-Ub assays, in contrast to the binding of hsGR-D
to the Nt-half of hsUBR1 (Fig. 4C), remains to be understood.
One possibility, to be addressed in future studies of hsGR vs. the
Arg/N-degron pathway, is that this pathway mediates an early
degradation of newly formed hsGR molecules, before their
Fig. 5. Up-regulation of the hsGR transcription factor in 2-KO
HEK293T cells. (A) Main hsGR isoforms (detailed terminology of hsGR iso-
forms is more complex than the one shown here) (ref. 62 and refs. therein).
(B) Lanes 1 through 3, IB-based CHX chase, for 0, 3, and 6 h, with wild-type
HEK293T cells, using anti-hsGR antibody that recognizes hsGR isoforms
shown in A. Lanes 4 through 6, same as lanes 1 through 3, but wild-type cells
were incubated with GA at the beginning and during chase (SI Appendix,
Materials and Methods). Lanes 7 through 9, same as lanes 1 through 3, but
with 2-KO cell line #1. Lanes 10 through 12, same as lanes 4 through 6, but
with 2-KO cell line #1. Lanes 13 through 18, same as lanes 7 through 12, but
with 2-KO cell line #2. (C) Same as in B but a longer chemiluminescence
exposure.
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conformational maturation and/or interaction with other pro-
teins, including hsGR itself. Yet another unknown in this setting,
to be addressed by future experiments, is the possibility that a
strong up-regulation of all isoforms of hsGR in 2-KO cells
(Fig. 5C) may be caused, in part, by effects of the hsUBR1/
hsUBR2 ablation on, for example, the efficacy of translation of
hsGRmRNAs. In sum, while it is highly likely that at least hsGR-
D (and possibly all isoforms of hsGR) are targeted by the Arg/
N-degron pathway, the details of this circuit and whether the role
of hsUBR1/hsUBR2 is solely degradative or has nonproteolytic
aspects as well, remain to be understood.
Concluding Remarks. It is still an unproven assumption that all
functions of the Arg/N-degron pathway (Fig. 1) involve, in the
end, the destruction of a targeted protein substrate, as distin-
guished, for example, from a nondegradative modification of
substrate through its ubiquitylation by this pathway (2). On that
assumption, the remarkably large alterations in the levels of
some mRNAs and proteins that result from genetic ablation of
the hsUBR1/hsUBR2 E3 N-recognins in human HEK293T cells
(Figs. 2 and 3 and SI Appendix, Figs. S2–S13) are likely to be
caused, at least in part, by metabolic stabilization (and therefore
up-regulation) of specific TFs (repressors and/or activators)
in 2-KO mutant cells that lack hsUBR1/hsUBR2. One such
“promoter-based” model, for the strongly up-regulated hsADRB2
mRNA and its encoded protein, is described in this paper
(Fig. 2 B–D and SI Appendix, Fig. S8). Analogous and verifiable
models can also be developed, using the same logic, for other
hsUBR1/hsUBR2-impacted genes described in the present study.
Our earlier work identified hsATF3, a stress-inducible TF that
regulates hundreds of genes, as a short-lived substrate of the
Arg/N-degron pathway in ref. 42. In the present study, we
identified another major TF, the glucocorticoid receptor
(hsGR), as a second TF that interacts with hsUBR1 in split-Ub
assays and is strongly influenced, in ways described above, by the
ablation of hsUBR1/hsUBR2 (Figs. 4C and 5). A TF called
hsPREP1was also found to bind to hsUBR1 of the Arg/N-degron
pathway (Fig. 4B), suggesting that hsPREP1 is yet another hu-
man TF that is impacted, through degradation and/or otherwise,
by this proteolytic system.
All three TFs, while binding to the Nt-half of the 200-kDa
hsUBR1 E3, did not interact in split-Ub assays with full-length
hsUBR1 (Fig. 4). This binding pattern was first encountered in
studies of S. cerevisiae scCUP9, a transcriptional repressor, which
can bind unconditionally to the Nt-half of scUBR1 but would
bind to full-length scUBR1 only in the presence of short peptides
that bear destabilizing Nt residues and thereby can convert
scUBR1, upon its binding to these peptides, into a conformer
that can interact with scCUP9. As described in more detail
above, these properties of scCUP9-scUBR1 interactions underlie
the ability of the Arg/N-degron pathway to control peptide
transport in yeast, through the regulated (by short peptides)
degradation of the scCUP9 repressor (2, 35, 36). It remains to be
determined whether a human TF, such as, for example,
hsPREP1 (it is sequelogous to scCUP9) may regulate peptide
transport in mammals by being a conditionally short-lived sub-
strate of the Arg/N-degron pathway.
Given that three TFs of different structures were found to
bind to the Nt-half of hsUBR1 in split-Ub assays (hsATF3 is a
bZIP TF, hsGR is a zinc-finger TF, and hsPREP1 is a homeo-
domain TF) (Fig. 4) (42), it would be illuminating to identify all
or most human TFs (∼1,600 distinct TFs total) (63) that are bona
fide in vivo substrates of the Arg/N-degron pathway. Specific
degrons (binding sites) that hsUBR1 recognizes in the three TFs
remain to be determined as well. Yet another vista opened up by
the present study (and discussed above) is the function of the
Arg/N-degron pathway as a regulator of translation of specific
mRNAs, such as those that encode the NF-L and NF-M subunits
of neurofilaments (Fig. 3 and SI Appendix, Fig. S13A).
A large number of mRNAs and proteins that were found to be
either significantly or very strongly up-regulated or down-
regulated in 2-KO human cells that lacked hsUBR1/hsUBR2
has greatly exceeded our ability to follow up and explore these
findings in the present study. Consequently, these detailed re-
sults (Figs. 2–5 and SI Appendix, Figs. S2–S13) are likely to serve
for a long time as sources of mRNA and protein leads for ana-
lyzing circuits that involve the Arg/N-degron pathway. This
multifunctional proteolytic system has emerged as a regulator of
specific mammalian genes, in part through conditional targeting
of TFs that include ATF3, GR, and PREP1.
Materials and Methods
For further information, see SI Appendix, Materials and Methods.
RNA-Seq Analyses. RNA-seq was carried out with RNA preparations from
wild-type vs. 2-KO (UBR1−/− UBR2−/−) HEK293T cell lines using methods de-
scribed in SI Appendix, Materials and Methods.
Quantitative Mass Spectrometric (TMT-SPS-MS3) Protein Analyses. MS-based
analyses of extracts from wild-type and 2-KO HEK293T cells employed the
TMT-SPS-MS3 technique, described in SI Appendix, Materials and Methods.
Cell Viability and Proliferation Assay. Cell viability and proliferation were
assayed using the Trypan Blue exclusion test, as described in SI Appendix,
Materials and Methods.
Cell Toxicity Assay with Dimethyloxalylglycine. This assay, which uses DMOG to
probe relative in vivo levels of the hsMCT2 transporter, is described in SI
Appendix, Materials and Methods.
Immunoblotting and Chase-Degradation Assays. IB analyses and chase-
degradation assays were carried out largely as described previously (23,
26) and in SI Appendix, Materials and Methods.
Split-Ubiquitin Assay. A version of split-Ub binding assay (Fig. 4A) (43) was
carried out in S. cerevisiae as described previously (26, 42, 60) and in SI
Appendix, Materials and Methods. Standard techniques were used for
construction of S. cerevisiae strains and transformation by DNA.
Data Availability. All relevant data are included in the article and supporting
information.
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